New yellow fever vaccine shows promise in early human trial
NCT ID NCT02743455
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new yellow fever vaccine (MVA-BN-YF) in 92 healthy adults aged 18-45. Some volunteers received the vaccine alone, some with an adjuvant (ISA 720) to boost the immune response, and others received a placebo or a different vaccine. The main goal was to check safety and how well the body's immune system responds. Since this is a Phase I trial, it is too early to know if the vaccine will prevent yellow fever.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN Yellow Fever Vaccine with or without Montanide ISA 720 adjuvant
What this could lead to
If successful, this could lead to a new, safer yellow fever vaccine that may be easier to produce and distribute.
What could go wrong
This is an early Phase I trial with only 92 people, so it is too soon to know if the vaccine works. Side effects are possible, and the results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
University of Iowa - Vaccine Research and Education Unit
Iowa City, Iowa, 52242-2600, United States